Biogen (BIIB) Tops Q4 EPS by 34c, Offers FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) PT Lowered to $280 at RBC Capital
January 30, 2020 1:09 PM ESTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $280.00 (from $285.00) while maintaining a Sector Perform rating following results.
solid quarter and optimist guidanceremain on sidelines given adu risks and near-term IP/competitive threats to core franchises... More